secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001171843-25-004211
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned
--------------------------------------------------------------------------------

- Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).
- More mice achieved seizure freedom: 11/32 simufilam vs. 3/29 vehicle (p=0.0343).
- Human safety data from 1,929-patient Phase 3 Alzheimer's studies show favorable safety profile with no serious SAEs attributed to drug.
- Company plans to initiate first clinical study in TSC-related epilepsy in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/0001171843-25-004211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/f8k_062925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer